SABCS 2020 | IMpassion031: patient-reported outcomes

Nadia Harbeck, MD, PhD, LMU Munich, Munich, Germany, outlines patient-reported outcomes from the Phase III IMpassion031 trial (NCT03197935) of neoadjuvant atezolizumab and chemotherapy in early, triple-negative breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).